Thoratec Seeks Less Invasive VAD Access With Apica Acquisition
This article was originally published in The Gray Sheet
The completed deal calls for $35 million up front and $40 million in future clinical and sales milestones. Apica is developing systems to assist transapical surgical access for ventricular assist devices and transcatheter valve replacements.
You may also be interested in...
Thoratec reported a near 10 percent year-over-year decline in revenue in the second quarter; physicians have become more selective about which patients to implant with a HeartMate II ventricular assist device, the firm says. The company is looking to next-generation of HeartMate products as well as the technology it acquired in the Apica deal to help it return to growth.
Apica Cardiovascular is leading the field of transapical access and closure for structural heart disease. Its first product is a titanium coil that stabilizes the surgical access site in the apex of the heart to prevent bleeding during and after therapeutic interventions and provides for reaccess in the future. Also in the works are a large closure device for transfemoral access closure and a connector that aids in the delivery and implantation of newer, smaller, left ventricular assist devices through the Apica coil.